Biotest AG / Key word(s): Personnel
Biotest AG: Dr Michael Ramroth to become new CEO of Biotest AG
07-March-2019 / 16:41 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Dr Michael Ramroth to become new CEO of Biotest AG
Dreieich, 7 March 2019. The Supervisory Board of Biotest AG, in its meeting today, appointed Dr. Michael Ramroth (58) as Chairman of the Board of Management (CEO) effective May 1st, 2019. He will take over the role as CEO from Dr. Bernhard Ehmer (64) whose appointment will then end after four and a half years for reasons of age.
Dr Ramroth has been a member of the Board of Management of Biotest AG since 2004. He joined Biotest from a position as Chairman for Business Development at Metallgesellschaft Technologies AG. From 1999 he had worked as CFO for the same company. From 1997 to 1999 he was CEO of CeramTec AG and from 1990 to 1997 Director of Business Development at Metallgesellschaft AG. Dr Ramroth is a lawyer and has a doctorate in economics.
Besides Dr Michael Ramroth as CEO, Dr Georg Floss will continue to be a member of the Board of Management of Biotest as COO. Dr Floss will assume additional responsibilities starting May 1st, 2019.
Biotest AG is very pleased that Dr Bernhard Ehmer will be available for consulting services in strategic projects.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
07-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|